Related Experiment Video
Updated: Nov 15, 2025
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
Published on: August 29, 2016
Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
Wout Devlies1,2, Florian Handle3, Gaëtan Devos2
1Laboratory of Molecular Endocrinology, KU Leuven, 3000 Leuven, Belgium.
Abstract:
Prostate cancer is an androgen-driven tumor. Different prostate cancer therapies consequently focus on blocking the androgen receptor pathway. Clinical studies reported tumor resistance mechanisms by reactivating and bypassing the androgen pathway. Preclinical models allowed the identification, confirmation, and thorough study of these pathways. This review looks into the current and future role of preclinical models to understand resistance to androgen receptor-targeted therapies. Increasing knowledge on this resistance will greatly improve insights into tumor pathophysiology and future treatment strategies in prostate cancer.
Insights
Prostate cancer therapies targeting the androgen receptor pathway face resistance. Preclinical models are crucial for studying these resistance mechanisms and improving future prostate cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Prostate cancer is driven by androgens, making androgen receptor pathway blockade a key therapeutic strategy.
- Tumor resistance to these therapies can emerge through pathway reactivation or bypass mechanisms.
- Understanding resistance is critical for advancing prostate cancer treatment.
Purpose of the Study:
- To review the role of preclinical models in understanding resistance to androgen receptor-targeted therapies in prostate cancer.
- To highlight the current and future applications of preclinical models in this field.
Main Methods:
- Literature review of preclinical models used in prostate cancer research.
- Analysis of studies investigating androgen receptor pathway resistance mechanisms.
- Synthesis of findings on the utility of preclinical models for therapeutic development.
Main Results:
- Preclinical models have been instrumental in identifying and confirming resistance pathways.
- These models facilitate in-depth study of tumor pathophysiology related to treatment resistance.
- Current research increasingly utilizes preclinical models to explore novel therapeutic strategies.
Conclusions:
- Preclinical models are essential tools for dissecting resistance to androgen receptor-targeted therapies.
- Continued use and development of preclinical models will enhance understanding of prostate cancer pathophysiology.
- This knowledge is vital for developing more effective future treatments for prostate cancer.
